Back to top

Tvardi downgraded to Market Perform from Outperform at Raymond James

Raymond James downgraded Tvardi Therapeutics (TVRD) to Market Perform from Outperform without a price target The firm believes many open questions ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Tvardi Therapeutics, Inc. (TVRD)